HomeACADEMIA
ACADEMIA

“Authorized Biosimilars” Could Be Priced at 50% of Originators: Prof.
(May.23.2017)

Prof. Hiroyuki Sakamaki
“Authorized biosimilars” (ABs) that are identical to originators in terms of manufacturing methods and facilities could be priced at 50% of the originals, just like first generics, instead of the current 70% rule for biosimilars in Japan, a key clinical economics expert predicts ...
(LOG IN FOR FULL STORY)

News Calendar